PER
Click for more information
4.94% 8.5¢ percheron therapeutics limited

FDA approves Sareptas Srp901 for the whole population, page-15

  1. lordolean
    2,904 Posts.
    lightbulb Created with Sketch. 45
    clock Created with Sketch.
    21/06/24
    17:07
    Post #: 74430730
    cant help but think this is helpful. It means the FDA is on side with the patient population and will have a bias toward approval. The negative for PER is clearly that they are not a Major US drug producer (as the FDA is biased toward approving drugs from its own).......but of the 2 I hope the former is a stronger pull factor......you need to have the patient groups onside which I believe PER does
    PER Price at posting: 8.7¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch. 1  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Tenant turnover: Reducing costs and revenue-loss
right-arrow Created with Sketch.
SUN ANZ deal to buy Suncorp to go ahead following approval from Treasurer
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
ABY Adore Beauty buys up wellness brand iKOU for $25M cash
right-arrow Created with Sketch.
SFX Sheffield Resources achieves milestone production, shipments at Thunderbird, WA
right-arrow Created with Sketch.
3DP Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.5¢ 		Change
0.004(4.94%) 		Mkt cap ! $76.63M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $46.54K 563.7K

Buyers (Bids)

No. Vol. Price($)
2 164616 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 100110 1
View Market Depth
Last trade - 15.55pm 28/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.